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Construction and Nonclinical Testing of a Puumala Virus Synthetic M
Gene-Based DNA Vaccine
R. L. Brocato,a M. J. Josleyn,a V. Wahl-Jensen,a,b C. S. Schmaljohn,c J. W. Hoopera
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USAa; Integrated Research Facility at Fort Detrick, Division
of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USAb; Science and Technology, United
States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USAc
Puumala virus (PUUV) is a causative agent of hemorrhagic fever with renal syndrome (HFRS). Although PUUV-associated
HFRS does not result in high case-fatality rates, the social and economic impact is considerable. There is no licensed vaccine or
specific therapeutic to prevent or treat HFRS. Here we report the synthesis of a codon-optimized, full-lengthM segment open
reading frame and its cloning into a DNA vaccine vector to produce the plasmid pWRG/PUU-M(s2). pWRG/PUU-M(s2) deliv-
ered by gene gun produced high-titer neutralizing antibodies in hamsters and nonhuman primates. Vaccination with pWRG/
PUU-M(s2) protected hamsters against infection with PUUV but not against infection by related HFRS-associated hantaviruses.
Unexpectedly, vaccination protected hamsters in a lethal disease model of Andes virus (ANDV) in the absence of ANDV cross-
neutralizing antibodies. This is the first evidence that an experimental DNA vaccine for HFRS can provide protection in a hanta-
virus lethal disease model.
Puumala virus (PUUV), a virus of the genus Hantavirus in theBunyaviridae family, is responsible for the vast majority of
cases of hemorrhagic fever with renal syndrome (HFRS) in Scan-
dinavia, Europe, and Western Russia (1). Other notable hantavi-
ruses that cause disease in humans include Hantaan virus
(HTNV) and Seoul virus (SEOV), which cause disease predomi-
nantly in Asia; Dobrava virus (DOBV), which causes disease pre-
dominantly in the Balkans; and Sin Nombre virus (SNV) and
Andes virus (ANDV), which cause disease predominantly in the
southwestern United States and southern South America, respec-
tively. Like all members of the Bunyaviridae family, PUUVs are
enveloped viruses with trisegmented (S,M, and L), negative-sense
RNA genomes. The S gene segment encodes the nucleoprotein
(N), which interacts with the genomic RNA to form nucleocap-
sids. The M gene segment encodes the Gn and Gc surface glyco-
proteins, which are the targets of neutralizing antibodies found in
infected animals (2). The L genome segment encodes the RNA-
dependent RNA polymerase (3).
PUUV is carried by persistently infected bank voles (Myodes
glareolus). Human disease occurs when persons are exposed to
infected rodent excreta or secreta, by either inhalation, ingestion,
or a bite (4, 5). PUUV does not have the high lethality of other
hantaviruses, such asHTNV (15% case-fatality rate) or the viruses
that cause hantavirus pulmonary syndrome (HPS), SNV and
ANDV (35% case-fatality rate); however, there is a high level of
morbidity (3). There are no vaccines to prevent HFRS caused by
PUUV, and there are no specific drugs to treat this disease (6).
Patients receive supportive care including dialysis (7).
Attempts to produce vaccines against PUUV have included
killed virus vaccines (8), virus-like particles (9), and subunit vac-
cines. Most of the subunit vaccines have involved the N protein
produced in Escherichia coli, yeasts, mammalian cells, and chime-
ric hepatitis B virus (HBV) core particles (10–13). Hitherto, at-
tempts to produce vaccines that elicit high-titer neutralizing anti-
bodies against PUUV have been unsuccessful. Our approach to
developing hantavirus vaccines has been to construct DNA vac-
cines containing the full-length hantavirus M gene. We used this
approach to produce SEOV, HTNV, and ANDV M gene-based
DNA vaccines (14–16).We also constructed a plasmid containing
both the HTNV and ANDVM gene open reading frames (ORFs),
controlled by separate promoters (17). These constructs elicited
high-titer neutralizing antibodies in rodents or rabbits and non-
human primates (NHPs). None of these vaccines elicited high
levels of PUUV cross-neutralizing antibodies, although the
HTNV-ANDV combination plasmid elicited detectable PUUV
cross-neutralizing antibodies after a long-range boost (17). Im-
portantly, none of these vaccines cross-protected against PUUV
infection in a hamster infection model. Recently, we developed a
synthetic PUUV DNA vaccine, pWRG/PUU-M(s2), that was
shown to be immunogenic in hamsters and humans (18, 19). De-
tails of the construction of the vaccine and protection data have
not yet been reported. Here we report the experiments that led to
the development of pWRG/PUU-M(s2) and describe protection
experiments demonstrating that this experimental vaccine is ca-
pable of protecting hamsters not only from infection with PUUV
but also against lethal disease caused by Andes virus.
MATERIALS AND METHODS
Viruses, cells, and medium. PUUV strain K27 (20), PUUV strain Sot-
kamo (21), HTNV strain 76-118 (22), ANDV strain Chile-9717869 (23),
SEOV strain SR11 (24), and DOBV strain Dobrava (25) were propagated
in Vero E6 cells (Vero C1008; ATCC CRL 1586). Transient-expression
experiments were performed with COS cells (COS-7; ATCC CRL 1651).
Both cell types were maintained in Eagle’s minimum essential medium
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with Earle’s salts (EMEM) containing 10% fetal bovine serum (FBS), 10
mMHEPES, pH 7.4, and antibiotics (penicillin [100 U/ml], streptomycin
[100 g/ml], and gentamicin sulfate [50 g/ml]) at 37°C in a 5% CO2
incubator.
Construction of hantavirus M gene vaccine plasmids. Construction
of the HTNV M gene DNA vaccine plasmid pWRG/HTN-M(x) was de-
scribed previously (15). pWRG/PUU-M(x22) was constructed by reverse
transcription of viral RNA, followed by PCR amplification of cDNA, and
standard cloning techniques. RNA was removed by digestion with RNase
H at 37°C for 20 min. Forward and reverse primers were based on the
published primers used to clone the Hantaan virus M gene into pWRG/
HTN-M(x) and on PUUV sequences, respectively. The forward primer
was HTNMX (5=-GGCCGCGGCCGCGGATCTGCAGGAATTCGGCA
CGAGAGTAGTAGACTCCGCAAGAAACAGCA), and the reverse
primer was PUUM-R (5=-GCGCGGATCCTAGTAGTATGCTCCGCAG
GAAC). The forward primer included a NotI restriction site (underlined)
and 24 nucleotides upstream of theM genome segment noncoding region
that are important for expressing G1 in pWRG/HTN-M(x) (15). The
reverse primer included a BamHI restriction site (underlined). cDNAwas
purified by use of a PCR purification kit (Qiagen) and used as a template
in a PCR. Primers HTNMX and PUUM-R were included in the PCRmix,
which also included Platinum TaqHigh Fidelity DNA polymerase (Invit-
rogen); the PCR conditions were one 3-min cycle at 94°C followed by 30
cycles of 94°C for 30 s and 68°C for 8 min. The PCR product was cut with
NotI and BamHI and then ligated into NotI-BglII-cut pWRG7077 vector
to produce pWRG/PUU-M(x22). Note that the BamHI and BglII sites are
compatible for ligation, but the resulting sequence cannot be digested by
either enzyme.
A plasmid expressing PUUV Gn alone (pWRG/PUU-Gn) was made
using pWRG/PUU-M(x22) as the template. The Gn sequence was ampli-
fied by PCR and subcloned into the NotI and BglII sites of pWRG7077.
The forward primer was HTNMX (see above), and the reverse primer was
PUUG1R (5=-GCGCAGATCTAGCACTGGCAGCCCATACAATTAAC
TCTAGGACCAATAACACGCACC). The underlined G represents a nu-
cleotide change to knock out the XbaI site. A plasmid expressing PUUV
Gc alone (pWRG/PUU-Gc) was also made using pWRG/PUU-M(x22) as
the template. The Gc sequence was amplified by PCR and subcloned into
the NotI and BamHI sites of pWRG7077. The forward primer was
PUUG2F (5=-GGCCGCGGCCGCCACCATGTGGTGCGTGTTATTGG
TCCTAGAGTTAATTGTATGGGCTGCC), and the reverse primer was
PUUMXNEF (5=-GCGCGGATCCGGGGTAATTTAATTAGTAAAG).
The forward primer included a NotI restriction site (underlined), and the
single underlined C represents a nucleotide change to knock out the XbaI
site.
To produce optimized plasmids, codon-optimized genes were synthe-
sized by GeneArt (26) and subcloned into the NotI-BglII sites of the DNA
vaccine vector pWRG7077. The plasmids containing synthetic gene 1 (s1)
and synthetic gene 2 (s2) were denoted pWRG/PUU-M(s1) and pWRG/
PUU-M(s2), respectively. Note that the sequences from the NotI site to
theMgene start codon and from theMgene stop codon to the BamHI site
in all three PUUV plasmids [i.e., pWRG/PUU-M(x22), pWRG/PUU-
M(s1), and pWRG/PUU-M(s2)] are identical.
PMED vaccinations. Vaccinations using an XR1 particle-mediated
epidermal delivery (PMED) device (gene gun) (Powderject-XR1 delivery
device; Powderject Vaccines, Inc.) have been described previously (15,
16). Gene gun cartridges consisting of0.75 g of plasmid DNA coating
0.5 mg of gold were prepared and stored at 4°C, desiccated, until use.
Anesthetized outbred Syrian hamsters were vaccinated with four admin-
istrations per vaccination, at nonoverlapping sites on the shaved abdom-
inal epidermis, using 400 lb/in2 of helium pressure. Female macaques
were vaccinatedwith similar cartridges, and the same gene gun conditions
were used to vaccinate the hamsters; however, themonkeys received eight
administrations (four on the abdomen and four over the inguinal lymph
nodes) per vaccination. Hamsters andmonkeys were anesthetized during
the nonpainful gene gun procedure. The only visible effect was mild ery-
thema at the site of vaccination.
ND10 vaccinations.Hamsters were anesthetized using isoflurane. Fur
was removed from the vaccination site (i.e., abdomen) by use of clippers.
Vaccines composed of DNA-coated gold beads were delivered to the ven-
tral abdominal epidermis by use of a handheld disposable gene gun des-
ignated an ND10 device. The ND10 device utilizes compressed helium
(500 lb/in2) to deliver 1.0 mg of2-m gold beads (coated with 2 g of
plasmid DNA) through the intact stratum corneum into the underlying
ventral abdominal stratum epidermis in a skin target area that is1.5 cm
in diameter. A stand allowed the ND10 device to be discharged without
applying pressure to the abdomen of the hamster. In the clinic, the ND10
device is pressed on the vaccination site to release a safety mechanism
allowing discharge of the helium. In addition, this stand allows 4-mm
spacing between the barrel of the ND10 device and the skin surface.
Challenge with hantaviruses. Anesthetized Syrian hamsters were ex-
posed to infectious virus by either intramuscular (i.m.) injection to the
caudal thigh or intranasal (i.n.) administration. Hantaviruses adminis-
tered i.m. (2,000 PFU of PUUV or ANDV) were diluted in sterile phos-
phate-buffered saline (PBS) (pH 7.4) and administered in a volume of 0.2
ml. Hantaviruses administered i.n. (2,000 PFU of DOBV or 4,000 PFU of
ANDV) were administered in a volume of 50 l, at approximately 25 l
per naris, with a micropipette.
Immunoprecipitation. Radioimmunoprecipitation assays (RIPAs)
usingCOS cell lysates labeledwith Promix ([35S]methionine and [35S]cys-
teine; Amersham) were performed exactly as described previously (15).
The plasmid pWRG/PUU-M(x22) or the empty vector pWRG7077 was
transfected into COS cells. Cells were starved for 30 min in methionine-
and cysteine-free medium and then radiolabeled for 17 h in medium
containing 600 Ci of Promix (Amersham) per T-75 flask. Lysates were
made using 4% Zwittergent 3-14 (Calbiochem-Bering) RIPA lysis buffer
as described previously (27). Anti-PUUV polyclonal rabbit serum, anti-
PUUV Gn monospecific serum, or anti-PUUV Gc serum was used to
immunoprecipitate the viral glycoproteins. Reduced samples were run in
4 to 12% Bis-Tris SDS-PAGE gradient gels with morpholinepropanesul-
fonic acid (MOPS) running buffer (Invitrogen) at 200 V.
N-specific ELISA. The enzyme-linked immunosorbent assay (ELISA)
used to detect N-specific antibodies (N-ELISA) was described previously
(15, 16, 28). The antigen consisted of either truncated SEOV N (amino
acids 1 to 117) or truncated PUUVN (amino acids 1 to 117), expressed as
a histidine-tagged fusion protein in Escherichia coliBL21(DE3) (Novagen,
Inc.) by use of the pRSET plasmid (Invitrogen) and purified by affinity
chromatography onNi-nitrilotriacetic acid (Ni-NTA) columns (Qiagen).
The endpoint titer was determined as the highest dilution that had an
optical density (OD) greater than the mean OD for serum samples from
negative-control wells plus 3 standard deviations. The SEOV N antigen
was used to detect HTNV and DOBV N-specific antibodies, and the
PUUV N antigen was used to detect PUUV and ANDV N-specific anti-
bodies.
PRNT.Plaque-reduction neutralization tests (PRNT)were performed
using Vero E6 cells as previously described (15). HTNV, DOBV, and
ANDV plaques were stained with 5% neutral red (Gibco) after 1 week.
PUUV plaques were fed with an additional overlay containing Earle’s
basal minimal essential medium, 10 mM HEPES, 0.6% agarose, 8 mM
L-glutamine, 10% FBS, 1 nonessential amino acids, penicillin (100
U/ml), streptomycin (100 g/ml), and gentamicin (50 g/ml) on day 7
and then stained with neutral red on day 10. Plates were incubated for 2 to
3 days at 37°C after staining to allow resolution of visible plaques. The
50% PRNT titer (PRNT50 titer) was the highest serum dilution reducing
the number of plaques by 50% relative to the average number of plaques
in control wells that received medium alone.
Ethics. This research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to animals
and experiments involving animals and adheres to the principles stated in
the Guide for the Care and Use of Laboratory Animals (29). The facilities
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where this research was conducted are fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care Interna-
tional. All animal experiments were approved by USAMRIID’s Institu-
tional Animal Care and Use Committee.
Statistical analysis. Protection from challenge with PUUV neutraliz-
ing antibodies was determined using logistic regression. Estimated prob-
abilities were calculated using logistic regression by Probit. Comparison
of neutralization titers was done using Student’s t test. The effect of vac-
cine on survival outcome was assessed using a logistic regression model.
Analyses were conducted using Prism 5 (GraphPad) and SAS, version 8.2
(SAS Institute Inc.).
RESULTS
The first-generation PUUV DNA vaccine plasmid, pWRG/
PUU-M(x22), elicits Gn and Gc antibodies in nonhuman pri-
mates, but not in hamsters, and does not protect against infec-
tion.Wepreviously demonstrated that SEOVandHTNVMgene-
based DNA vaccines failed to cross-protect against PUUV in a
hamster infection model (15). Thus, to develop a candidate vac-
cine to protect against PUUV, we used reverse transcription and
PCR to amplify the PUUV M gene from RNA purified from
PUUV strain K27. This cDNA was cloned into our DNA vaccine
vector, pWRG7077, to produce pWRG/PUU-M(x22). The M
gene open reading frame sequence contained no insertions or de-
letions; however, there were 17 changes in the amino acid se-
quence compared to the published sequences for strain K27 and
other closely related strains (Table 1). pWRG/PUU-M(x22) was
evaluated for in vitro expression of Gn and Gc, and both proteins
were detected by immunoprecipitation (see Fig. S1A in the sup-
plemental material). pWRG/PUU-M(x22) was tested for immu-
nogenicity in hamsters, and the results indicated that there was no
antibody response, even after five vaccinations delivered by gene
gun (data not shown). In addition, hamsters were not protected
from PUUV infection as determined by ELISA 1 month after a
20,000-PFU intramuscular challenge (100 50% infective doses
[ID50]) (data not shown). In an earlier study, it was determined
that the ANDV M gene-based DNA vaccine failed to elicit a de-
tectable immune response or protection in hamsters but never-
theless elicited high-titer neutralizing antibodies in nonhuman
primates (17). Therefore, we tested the pWRG/PUU-M(x22) plas-
mid for immunogenicity in nonhuman primates. Three cynomol-
gus macaques were vaccinated with pWRG/PUU-M(x22). One of
the three (animal 6064) produced antibodies against the Gn and
Gc proteins andweak neutralizing antibodies (PRNT50 titer 40)
(data not shown). In a second NHP experiment, five rhesus ma-
caques were vaccinated with pWRG/PUU-M(x22) five times by
use of a gene gun. Four of the five animals developed antibodies
against Gn or Gc (see Fig. S1B). Only one animal (animal CH20)
produced detectable levels of neutralizing antibodies (PRNT50
titer 20). These data were encouraging, because it was the first
time that any PUUVDNA vaccine had produced antibodies to the
PUUV glycoproteins. However, the data indicated that improve-
ments in the quality of the immune response, i.e., the neutralizing
antibody response, were needed.
Synthetic, mammalian codon-optimized Puumala virus M
gene-based DNA vaccine pWRG/PUU-M(s2) elicits neutraliz-
ing antibodies in nonhumanprimates.Asnoted above, the amino
acid sequence of GnGc encoded by pWRG/PUU-M(x22) was not
identical to any published PUUV GnGc sequences (Table 1). It was
possible that one or more of these amino acid differences could
disrupt the conformation of the protein, including the conforma-
tions of epitopes bound by neutralizing antibodies. To detect pos-
sible deviations in the amino acid sequence, an alignment of sev-
eral published PUUV M gene ORFs was made. Five possible
nonconsensus amino acid residues were detected (Table 1). To
test whether optimizing the gene or changing to consensus amino
acids could improve the neutralizing antibody response, two
genes were synthesized and cloned into pWRG7077. The first syn-
thetic gene (s1) was amammalian codon-optimized version of the
ORF in pWRG/PUU(x22). This new plasmid was called pWRG/
PUU-M(s1). The second synthetic gene was identical to that in
pWRG/PUU-M(s1); however, the five amino acids that were
unique to pWRG/PUU-M(x22) were changed to the consensus
amino acids identified inTable 1. The newplasmid containing this
gene was called pWRG/PUU-M(s2).
To determine if nucleic acid changes in pWRG/PUU-M(s1) or
nucleic acid and amino acid changes in pWRG/PUU-M(s2) could
affect the immune response elicited by these DNA vaccines, an
experiment was performed in which groups of three rhesus ma-
caques were vaccinated with pWRG/PUU-M(x22), pWRG/PUU-
M(s1), or pWRG/PUU-M(s2). Sera collected at the indicated
times were tested for the capacity to neutralize PUUV strain K27.
PRNT data indicated that one or more of the five amino acid
changes made in the synthetic gene in the pWRG/PUU-M(s2)
DNA vaccine resulted in a dramatic increase in the neutralizing
antibody response (Fig. 1A). Titers were all higher than 100 after
the second vaccination, increased 2-fold to 4-fold after the third
vaccination, and then declined to just detectable levels by week 18.
Upon booster vaccination on week 19, the titers in all animals
increased 4- to 64-fold. Neither the pWRG/PUU-M(s1) nor
pWRG/PUU-M(x22) vaccine elicited neutralizing antibodies
with a titer of 20, indicating that gene optimization alone was
TABLE 1 Comparison of differences in deduced M segment open
reading frame amino acids for four strains of PUUV and three DNA
vaccine constructsf
Amino acid
positiona
PUUVM segment amino acid DNA vaccine amino acid
DTK/
Ufa-97b K27c P360d
Hallnas
B1e
PUU-
M(x22)
PUU-
M(s1)
PUU-
M(s2)
10 Y Y C Y Y Y Y
38 V I I I I I I
187 Q Q Q D Q Q Q
207 H H H H Y Y H
312 A A A V A A A
416 L S L L L L L
448 M M M M T T M
492 W W W W R R W
501 F L F F F F F
604 T T T R T T T
649 L L L H L L L
650 E E E H E E E
675 G G G R G G G
690 P P P Q P P P
972 Q Q Q Q R R Q
1077 G G G P G G G
1097 S S S S L L S
a M gene segment open reading frame amino acid position.
b DTK/Ufa-97, PUUV strain DTK/Ufa (GenBank accession no. BAF49040).
c K27, PUUV strain K27 (GenBank accession no. P41265).
d P360, PUUV strain P360 (GenBank accession no. P41266).
e Hallnas B1, PUUV strain Hallnas B1 (GenBank accession no. P21400).
f Amino acids shown in bold are differences with respect to the PUUM(s2) sequence.
Brocato et al.
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insufficient to correct the deficiencies in the original pWRG/PUU-
M(x22) plasmid.
Having determined that pWRG/PUU-M(s2) was capable of
eliciting neutralizing antibodies against PUUV strain K27, we
tested the sera from week 10 (after 3 vaccinations) or week 18
(after 4 vaccinations) for the capacity to neutralize the distantly
related Sotkamo strain of PUUV. The Sotkamo strain of PUUV,
isolated in Finland, has 63 amino acids that differ from the M
segment sequence encoded by the PUUVMgene in pWRG/PUU-
M(s2). Nevertheless, antibodies produced in theNHPs vaccinated
with pWRG/PUU-M(s2) efficiently neutralized PUUV strain Sot-
kamo, and the differences in titers were statistically significant
[P  0.0001 for comparing each titer to its pWRG/PUU-M(s1)
and pWRG/PUU-M(x22) counterparts, which did not elicit de-
tectable neutralizing antibodies] (Fig. 1B). The PRNT50 titers were
similar for both strain K27 and strain Sotkamo. These data sug-
gested that the pWRG/PUU-M(s2) vaccine would cross-protect
against divergent PUUV strains found in Northern Europe and
Western Russia.
The week 10 and 18 sera were also tested for the capacity to
cross-neutralize HTNV, SEOV, and DOBV. There was no cross-
neutralizing antibody against SEOV or DOBV, and only one of
three NHPs (animal 6693, week 19) exhibited weak (titer of 20)
cross-neutralizing activity against HTNV (data not shown).
The pWRG/PUU-M(s2) DNA vaccine delivered using a
handheld particle-mediated epidermal delivery device (i.e.,
ND10 device) elicits antibodies in hamsters. We tested the
pWRG/PUU-M(s2) PUUV DNA vaccine in hamsters by using a
research gene gun and found that the vaccine efficiently elicited
neutralizing antibodies (19). Thus, the changes in pWRG/PUU-
M(s2) overcame the absence of immunity in hamsters observed
for vaccinationwith pWRG/PUU-M(x22). This was an important
finding because it allowed us to use a small-animal model for
testing vaccine potency and protective efficacy.
Having successfully constructed immunogenic hantavirus M
gene-based DNA vaccines against the HFRS hantaviruses, we ini-
tiated preclinical testing of these vaccines, delivered using a hand-
held particle-mediated epidermal delivery device (gene gun) de-
signed for human use, known as an ND10 device. Two lots of
ND10 devices loaded with pWRG/PUU-M(s2) and two lots of
ND10 devices loaded with pWRG/HTN-M(x), hitherto referred
to as the PUUV DNA vaccine and HTNV DNA vaccine, respec-
tively, weremanufactured according to goodmanufacturing prac-
tices (GMP). Product stability studies were performed on the four
GMP lots of vaccine. In the first study, two lots of vaccine were
evaluated after 0, 3, 6, 9, and 12 months of storage at 4°C. As part
of the stability studies, the vaccines were tested for potency by
measuring their capacity to elicit neutralizing antibodies in ham-
sters. At each of the aforementioned time points, groups of 8 to 10
Syrian hamsters were vaccinated by use of ND10 devices on a
compressed schedule (weeks 0, 2, and 3), which was used instead
of amore lengthy schedule to complywith necessary potency assay
timelines. Sera collected on vaccination weeks 0 and 4 were tested
for neutralizing antibodies by PRNT (Fig. 2A). The HTNV DNA
vaccine and PUUVDNA vaccine resulted in 98% (44/45 animals)
and 88% (44/50 animals) seroconversion, respectively. Over the
course of 1 year, the neutralizing antibodies produced in individ-
ual potency test hamsters ranged from20 to 5,120, and geomet-
ric mean titers (GMTs) for the groups at different time points
ranged from 302 to 666 for the HTNVDNA vaccine. The neutral-
izing antibody titers for the PUUVDNAvaccine ranged from20
to 20,480, and GMTs for groups at different time points ranged
from 53 to 408. In the second stability study, two lots of vaccine
were evaluated after 0, 3, 6, 9, 12, 18, or 24months of storage at 4°C
(Fig. 2B). The HTNV DNA vaccine and PUUV DNA vaccine re-
sulted in 100% (67/67 animals) and 95%(63/66 animals) serocon-
version, respectively. Over the course of 2 years, the neutralizing
antibody titers ranged from 40 to 40,960, and GMTs ranged from
226 to 1,631 for the HTNV DNA vaccine. The neutralizing anti-
body titers for the PUUV DNA vaccine ranged from 20 to
40,960, and GMTs ranged from 113 to 3,883. These data clearly
demonstrated that the candidate PUUV DNA vaccine and the
HTNV DNA vaccine remained immunogenic for at least 2 years
when stored at 4°C.
PUUV DNA vaccine (delivered via ND10 device) protects
hamsters against infection with PUUV. Having found that the
PUUV DNA vaccine elicited neutralizing antibodies, it was im-
FIG1 PUUVDNAvaccine testing in nonhuman primates. (A)Neutralization
of PUUV strain K27. Groups of three rhesus macaques were vaccinated (indi-
cated by arrows) with either pWRG/PUU-M(s1), pWRG/PUU-M(s2), or
pWRG/PUU-M(x22). Sera collected on the indicatedweeks were tested for the
capacity to neutralize PUUV strain K27. Each symbol represents the GMT for
2 or 3 PRNT50 assays. (B) Cross-neutralization of PUUV strain Sotkamo. Sera
collected after 3 (week 5) or 4 (week 19) vaccinations were tested by a PRNT
using PUUV strain Sotkamo. The PRNT limit of detection was a titer of 20
(dashed line).
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portant to determine if the vaccine could confer protective immu-
nity. The PUUV DNA vaccine was tested for the capacity to pro-
tect against infection with homotypic or heterotypic hantaviruses.
In the first two experiments, groups of hamsters were vaccinated
with either the PUUV DNA vaccine or the HTNV DNA vaccine
and then challenged with PUUV by the i.m. route either 1 month
(experiment 1) or 4 months (experiment 2) after vaccination.
PUUV does not cause disease in hamsters; however, evidence of
infection can be detected bymeasuring the presence or absence of
antibodies to the viral nucleocapsid (N) protein after challenge
(30). Pre- and postchallenge sera were run in N-ELISA. All pre-
challenge serum samples were negative by ELISA (data not
shown). In both experiments, 80% and 90% (4 weeks and 10
weeks after vaccination, respectively) of the hamsters did not have
detectable anti-N antibodies, indicating that these animals were
protected against PUUV infection (Fig. 3A). These results were
statistically significant (P  0.0001 compared to unvaccinated
hamsters). In contrast, the hamsters that were not vaccinated or
were vaccinated with the HTNVDNA vaccine were not protected
(i.e., anti-N antibodies were detected in all of the hamsters). The
latter data confirmed our earlier finding that the HTNV DNA
vaccine does not protect against PUUV infection (15).
We next determined if the PUUV neutralizing antibody titer
could predict protective immunity against PUUV. PRNT and
ELISA titers for sera collected pre- and postchallenge for ex-
periments 1 and 2 in Fig. 3A were evaluated to determine the
relationship between evidence of a vaccine “take” (i.e., positive
PRNT titer after vaccination) and protection (i.e., negative
ELISA titer after challenge). In general, the presence of PUUV
neutralizing antibodies in the prechallenge sera was predictive
of protective immunity (Table 2). There were two exceptions
that are discussed further in Discussion. Results of logistic re-
gression indicated that the log10 titer was significantly associ-
FIG 2 In vivo stability testing of HTNV and PUUV DNA vaccines delivered using a handheld single-use gene gun (ND10). (A) Lot 1 of each vaccine was tested
for immunogenicity over 1 year. (B) Lot 2 of each vaccine was tested for immunogenicity over 2 years. Symbols represent the neutralizing antibody PRNT50 titers
for individual hamsters vaccinated with either pWRG/HTN-M(x) or pWRG/PUU-M(s2). Hamsters vaccinated with theHTNVDNA vaccine were evaluated for
HTNV neutralizing antibodies, and hamsters vaccinated with the PUUVDNA vaccine were evaluated for PUUV strain K27 neutralizing antibodies. The PRNT
limit of detection was a titer of 20 (dashed line).
FIG 3 Evaluation of protection (PUUV) and cross-protection (DOBV) in
hamster infection models. Groups of 6 to 8 hamsters were vaccinated (week 0,
2, or 3)with PUUVDNAvaccine,HTNVDNAvaccine, or no vaccine and then
challenged with PUUV strain K27 or DOBV. (A) Hamsters were challenged
either 4 weeks or 12 weeks after the last vaccination, using an intramuscular
challenge of 2,000 PFU PUUV. (B) Hamsters were challenged 11 weeks after
the last vaccination, using an intranasal challenge of 2,000 PFU DOBV. Sera
were collected at 35 days postchallenge, and N-ELISA log10 titers were plotted.
The N-ELISA limit of detection was a titer of 2 log10 (dashed line).
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ated with the protection outcome. Each unit log10 increase in
the prechallenge PUUV PRNT50 titer was associated with an
increase in the odds of protection against PUUV infection of
7.8 times (P  0.0001).
PUUV DNA vaccine (delivered via ND10 device) does not
cross-protect hamsters against infection with DOBV. We next
determined if the PUUVDNA vaccine could cross-protect against
infection with DOBV. To test this, groups of hamsters were vac-
cinated with the PUUV DNA vaccine as described above. A con-
trol group of hamsters was vaccinated with the HTNV DNA vac-
cine, which had previously been shown to protect hamsters
against DOBV (15). Eleven weeks after the last vaccination, ham-
sters were challenged with DOBV by the i.n. route. The i.n. route
of exposure was tested to gain additional information on the ca-
pacity of hantavirus DNA vaccines to confer protection against a
mucosal challenge. Like PUUV, DOBV does not cause disease in
hamsters but readily infects hamsters by the i.m. or i.n. route (15;
unpublished data). Sera collected 35 days after i.n. DOBV chal-
lenge were evaluated by N-ELISA (Fig. 3B). The PUUVDNA vac-
cine did not protect against DOBV infection. In contrast, the
HTNV DNA vaccine did protect against an i.n. challenge with
DOBV (P  0.0170). In this experiment, there were no DOBV
cross-neutralizing antibodies detected in hamsters vaccinated
with the PUUV or HTNV DNA vaccine (data not shown). Thus,
the HTNV M gene-based DNA vaccine, but not the PUUV DNA
vaccine, was protective against a mucosal challenge with DOBV,
even in the absence of detectable levels of cross-neutralizing anti-
bodies.
PUUVDNA vaccine cross-protects hamsters against a lethal
challenge with ANDV. The PUUV and DOBV infection models
described above require sterilizing immunity (i.e., no evidence of
an antibody response to the challenge virus nucleocapsid protein)
for a positive readout. It is possible that a vaccine that fails to
protect against infection might still be capable of preventing dis-
ease. There are no practical HFRS disease models for testing can-
didate hantavirus vaccines; however, there is a disease model for
hantavirus pulmonary syndrome (HPS). When Syrian hamsters
are exposed to ANDV, they develop a lethal disease that closely
resembles HPS in humans (14, 23, 31–36). Recombinant adeno-
virus and vesicular stomatitis virus vectors encoding ANDV N or
glycoproteins have been shown to protect against lethalHPS in the
hamster model (34, 37). In an earlier study, we found that the
HTNVM gene-based DNA vaccine conferred partial but not sta-
tistically significant protection against an i.m. challenge with
ANDV (14). Nevertheless, we hypothesized that the PUUV DNA
vaccine might be capable of protecting against lethal disease
caused by ANDV, because PUUV andANDVGn andGc aremore
closely related on the amino acid level than theHTNV and ANDV
proteins (66.5% versus 54.9% identity). To test this, we first per-
formed two experiments where groups of hamsters were vacci-
nated with either the PUUV DNA vaccine or the HTNV DNA
vaccine or not vaccinated and then challenged (either 14 or 20
weeks later)with 4,000 PFUofANDVby the i.n. route. The PUUV
DNA vaccine, but not the HTNV DNA vaccine, conferred a sig-
nificant level of protection against lethal HPS in both experiments
(Fig. 4A and B), with P values of 0.0428 (14 weeks) and0.0001
(20 weeks).
Another experiment was conducted using the more rigorous
i.m. route of exposure (the 50% lethal dose [LD50] by the i.n. route
is 95 PFU, and the LD50 by the i.m. route is 8 PFU) (23, 33).
Hamsters were vaccinated with the PUUVDNA, HTNVDNA, or
no vaccine as described above and then challenged (7 weeks later)
by the i.m. route with ANDV. The PUUV DNA vaccine elicited a
significant level of protection against intramuscular challenge
(Fig. 4C), with a P value of 0.0062. As reported previously, the
HTNVDNAvaccine elicited partial but not significant protection.
Interestingly, the PUUV DNA vaccine elicited only low-level
(PRNT50 titer 20) ANDV cross-neutralizing antibodies in pre-
challenge sera of half of the hamsters (data not shown). Thus, we
concluded that neutralizing antibodies produced by theDNAvac-
cines, while sufficient to protect, are not necessary to confer cross-
protection against lethal hantavirus disease.
DISCUSSION
Early attempts to clone full-length hantavirus M segments into
expression plasmids resulted in clones with nonsense mutations
in the ORFs that typically resulted in truncated Gn or Gc proteins,
or other disruptive mutations. These included single nucleotide
deletions/substitutions and large insertions (i.e., integration of in-
sertional elements such as IS5). It is possible that the M gene nu-
cleotide sequence is somehow toxic to E. coli and that this toxicity
results in negative selection against full-length clones with the
correct sequence. When we finally succeeded in cloning a full-
length PUUVM gene with an intact ORF [plasmid pWRG/PUU-
M(x22)], there were still a number of nucleotide changes that
resulted in unique amino acid changes relative to published se-
quences. At least one of these changes presumably altered the
Gn-Gc structure such that the pWRG/PUU-M(x22) DNA vaccine
was only capable of eliciting nonneutralizing or low-titer neutral-
izing antibodies. By employing synthetic biology, it was possible
TABLE 2 PUUV neutralizing antibodies and protection against PUUV
infection
Vaccinea Hamster ID
Prechallenge
PUUV
PRNT50
titerd
Postchallenge
N-ELISA titer
(log10)
b,d Protectionc
pWRG/
PUU-M(s2)
269 5,120 3 N
262 2,560 1 Y
261, 263 1,280 1 Y
243 640 1 Y
248 320 2 N
266 320 1 Y
245, 264, 267 160 1 Y
242, 244, 249, 270 80 1 Y
241 40 1 Y
246, 250, 268 20 1 Y
265 1 2 N
None 298 40 3 N
281, 284 20 3 N
282 20 2 N
283 1 2 N
285, 286 1 3 N
287 1 4 N
288, 290, 978, 980 1 3 N
291 1 2 N
292, 293–295, 297 1 3 N
pWRG/
HTN-M(x)
251, 252, 254, 258–260,
232, 236, 239, 240
1 3 N
253, 256, 231, 237 1 4 N
a Hamsters were vaccinated on weeks 0, 2, and 3 by use of ND10 delivery devices.
b Log10 endpoint titers represent GMTs for two N-ELISAs.
c A postchallenge N-ELISA titer of2 indicates that the hamster was protected. N, not
protected; Y, protected.
d A value of 1 indicates that the titer was below the limit of detection. The limit of
detection for the PRNT was 20, and the limit of detection for the ELISA was 2 (log10).
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not only to correct the amino acid changes but also to alter the
entire ORF such that the sequence was no longer toxic in E. coli
(via codon optimization). These changes resulted in a DNA vac-
cine, pWRG/PUU-M(s2), that was readily propagated in E. coli
(data not shown) and capable of eliciting high-titer neutralizing
antibodies. This was the first time that any molecular PUUV vac-
cine had elicited high-titer neutralizing antibodies in any species.
Future research will employ the same strategy to develop candi-
dateM gene-based DNA vaccines against other hantaviruses. This
is a powerful approach because all that is required is the full-length
M gene ORF sequence information.
Using synthetic biology, it would be possible to produce DNA
vaccine plasmids against all of the known pathogenic strains of
hantaviruses; however, from a vaccine development perspective,
this would be expensive, impractical, and unnecessary. We and
others have demonstrated that neutralizing antibodies are suffi-
cient to protect against infection and/or disease (14, 15, 31, 37,
38). Thus, the production of cross-neutralizing antibodies is a
reasonable predictor that the vaccine will be cross-protective. For
example, pWRG/PUU-M(s2) is based on PUUV strain K27 from
Western Russia, and we demonstrated that the neutralizing anti-
bodies produced by this vaccine readily cross-neutralize PUUV
strain Sotkamo, from Scandinavia. There is approximately 94.3%
identity in the M segment amino acid sequences between these
viruses. From this, we predict that pWRG/PUU-M(s2) will be
protective against strains of PUUV found in Russia and Scandina-
via. Additional cross-neutralization experiments utilizing other
PUUV strains will be needed to determine the breadth of cross-
reactivity.
To start defining the level of neutralizing antibodies that pre-
dicts protective immunity, we performed a statistical analysis
comparing prechallenge neutralizing antibody titers with protec-
tion data. A PRNT50 titer of22 gave an estimated probability of
protective immunity of 60%, and a titer of119 gave an estimated
probability of protective immunity of 90%, with 95% certainty
(Table 3). Thus, neutralizing antibodies produced by vaccination
with hantavirus vaccines can be used to predict the probability
that the vaccination will be protective. There were individual an-
imals thatwere exceptions. For example, the hamster (animal 269)
with the highest PUUV PRNT titer (5,120) was nevertheless in-
fected with PUUV as measured by ELISA (Table 2). It is possible
that the PRNT or ELISA results for animal 269 were produced in
error (e.g., by tube mislabeling), or it is possible that an animal
with a very potent neutralizing antibody response can still be in-
fected. Because we cannot rule out the possibility of a technical
error, and because the number of exceptions is low, we are basing
our conclusions on the aggregate data set shown inTable 2 and the
statistical analysis shown in Table 3. In that analysis, the presence
of neutralizing antibodies is predictive of protection. As more
neutralizing antibody/protection data are compiled, the precise
relationship between neutralizing antibodies and protection will
become evident, and a better estimate of what constitutes a pro-
tective titer will be generated. In addition, passive transfer exper-
iments will be used to determine what neutralizing antibody titer,
in the absence of a cell-mediated immune response, is sufficient to
confer protection.
The HTNVDNA vaccine did not elicit DOBV cross-neutraliz-
ing antibodies in the ND10 experiment shown in Fig. 1, but nev-
ertheless, it protected hamsters against DOBV infection. It is pos-
sible that low levels of neutralizing or otherwise protective
TABLE 3 Calculation of estimated probabilities of protective immunity
against PUUV infection based on the protection data from Table 2
Estimated probability
of protective
immunitya
Prechallenge
PUUV
PRNT50 titer
Lower 95%
fiducial
limit
Upper 95%
fiducial
limit
0.40 24 8 77
0.50 37 13 148
0.60 59 22 305
0.70 97 35 713
0.80 177 58 2,122
0.90 438 119 11,700
a Determined by logistic regression by Probit. Protection status by titer was used to
calculate estimated probabilities of protective immunity.
FIG 4 PUUV DNA vaccine protects against lethal hantavirus disease. Groups
of 8 to 10 hamsters were vaccinated with the indicated vaccine or not vacci-
nated. Sixteenweeks (A) or 20weeks (B) elapsed before an intranasal challenge
of 4,000 PFU ANDV. (C) Groups of 9 or 10 hamsters were vaccinated with the
indicated vaccine or not vaccinated before an intramuscular challenge of 2,000
PFU ANDV. Survival of all animals was monitored for 35 days postchallenge.
ns, not significant.
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antibodies were present but not detected by classical PRNT. In
support of this, previous reports have demonstrated that the
HTNV DNA vaccine delivered by gene gun can elicit anti-DOBV
cross-neutralizing antibodies in hamsters and nonhuman pri-
mates (15). It is possible that the levels elicited by the ND10 ex-
periment were below detection but nevertheless capable of pre-
venting infection. Another possibility is that a cellular response
(e.g., the CD8 T cell response) elicited by the HTNV DNA vac-
cine, but not the PUUVDNAvaccine, is sufficient to protect ham-
sters fromDOBV infection. Others have shown that recombinant
adenovirus vectors containing ANDV Gn or Gc are capable of
protecting hamsters against lethal HPS in the absence of neutral-
izing antibodies (34). Presently, we do not have assays to measure
specific hamster T cell responses to hantavirus vaccines.
The PUUVDNA vaccine did not elicit ANDV cross-neutraliz-
ing antibodies, but it nevertheless protected hamsters against le-
thal infection with ANDV. This finding demonstrates that al-
though neutralizing antibodies are sufficient to confer protection,
they are not necessary. In an earlier study, the HTNV DNA vac-
cine partially protected hamsters from lethal HPS, but these re-
sults did not reach statistical significance (14). The fact that
PUUV-vaccinated hamsters were protected from lethal HPS re-
gardless of the route of ANDV challenge (either i.n. or i.m.) dem-
onstrates that an HFRS vaccine might have broader protective
efficacy than that predicted by cross-neutralization. If the mecha-
nism of cross-protection in the absence of neutralizing antibodies
is mediated by CD8 T cells, then our results indicate that PUUV
Gn andGc, but notHTNVGn andGc, share a sufficient protective
epitope(s) with ANDV Gn and Gc to confer protection. This cor-
responds to the overall amino acid identity of the glycoproteins:
PUUV Gn and Gc are 66.5% identical to ANDV Gn and Gc,
whereas HTNVGn and Gc are only 54.9% identical to ANDVGn
and Gc. It is possible that the PUUV DNA vaccine cross-protects
against disease caused by HTNV (the Gn-Gc identity of these vi-
ruses is 55.0%). At this time, an animal model of HFRS disease
suitable for vaccine testing does not exist. Suckling mice injected
intracerebrally with HTNV develop a lethal neurological disease
(39); however, suckling mice are not amenable to active vaccine
studies. Similarly, PUUV has been shown to cause some signs of
disease in macaques; however, the observed tissue pathology and
abnormalities in blood hematology and chemistry are not consis-
tent in all exposed animals (40–43). Thus, large numbers of non-
human primates would be needed to determine if amedical coun-
termeasure was effective at preventing disease. A caveat to this
would be if themedical countermeasure were effective at prevent-
ing infection. For suchmedical countermeasures, it would be pos-
sible to use either rodent (e.g., hamster) or nonhuman primate
models of infection (40–42, 44, 45).
As mentioned above, the HTNV and PUUV DNA vaccines
delivered by the ND10 gene gun were recently tested in a phase 1
clinical trial (18). In that trial, both hantavirus DNAs were shown
to be safe and immunogenic (i.e., elicited neutralizing antibodies)
in some but not all vaccines. Here we have demonstrated that
these vaccines delivered by the ND10 device can protect hamsters
not only against infection with PUUV and DOBV but also against
lethal disease caused by ANDV. This is the first time that active
vaccination with any DNA vaccine has been shown to protect
against lethal hantavirus disease in an animal model. Future clin-
ical trials will involve testing the immunogenicity of these vaccines
delivered by alternative technologies, such as muscle and skin
electroporation or needle-free jet injection. Although we know
that protection can occur in the absence of neutralizing antibod-
ies, a path to licensure of these vaccines will likely involve the use
of neutralizing antibodies produced in vaccinated humans as sur-
rogate markers of protective efficacy. Still, our finding that the
PUUVDNAvaccine can provide protection in an animalmodel of
lethal hantavirus disease (HPS caused by ANDV) might allow an
alternative pathway to licensure involving the animal rule (rule 21
CFR 601.90 for biological products).
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Supplemental Figure S1 
 
 
Suppl. Fig. 1. Pre-synthetic PUUV full-length M gene-based DNA vaccine.  A) Expression of PUUV Gn and Gc. 
The pWRG/PUU-M(x22), pWRG/PUU-Gn, pWRG/PUU-Gc plasmids or empty vector was used to transfect COS cells 
and the expressed proteins were detected by RIPA.   Alternatively, cells were infected with PUUV, strain K27, to 
serve as positive controls.  The antibodies used to detect the viral proteins were anti-PUUV polyclonal rabbit sera 
(anti-PUUV), anti-Gn rabbit sera (anti-PUU Gn), or anti-Gc rabbit sera (anti-PUU Gc).  The position of Gn and Gc are 
shown with arrows and red boxes.  In the case of PUUV infected cells, the N protein is also detected.  B) Antibody 
responses in macaques receiving 5 vaccinations with pWRG/PUU-M(x22).  Each gel represents RIPA results for a 
specific NHP (ID# CH20, CH14, W2C, DFG, CH60) with #6064 sera as a positive control.  The table represents a 
summary of the RIPA and PRNT data, + indicates expression detected, ++ indicates a higher level of expression 
detected, < indicates PRNT50 titer <20. 
